Patents by Inventor Tim Edmunds

Tim Edmunds has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody-based therapeutics with enhanced ADCC activity
    Patent number: 8071336
    Abstract: Methods for producing antibody-based therapeutics with enhanced ADCC activity are disclosed. The enhanced ADCC activity is attributed to oligomannose-type N-glycans on the antibodies and Fc fusion proteins of the invention. Also disclosed are methods of using such antibody-based therapeutics for targeted killing of cells in a mammal, including therapeutic methods of treating cancers, autoimmune diseases and other diseases.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: December 6, 2011
    Assignee: Genzyme Corporation
    Inventors: John M. McPherson, Tim Edmunds, Qun Zhou
  • ANTIBODY-BASED THERAPEUTICS WITH ENHANCED ADCC ACTIVITY
    Publication number: 20100184145
    Abstract: Methods for producing antibody-based therapeutics with enhanced ADCC activity are disclosed. The enhanced ADCC activity is attributed to oligomannose-type N-glycans on the antibodies and Fc fusion proteins of the invention. Also disclosed are methods of using such antibody-based therapeutics for targeted killing of cells in a mammal, including therapeutic methods of treating cancers, autoimmune diseases and other diseases.
    Type: Application
    Filed: February 12, 2010
    Publication date: July 22, 2010
    Inventors: John M. McPherson, Tim Edmunds, Qun Zhou
  • Antibody-based therapeutics with enhanced ADCC activity
    Patent number: 7700321
    Abstract: Methods for producing antibody-based therapeutics with enhanced ADCC activity are disclosed. The enhanced ADCC activity is attributed to oligomannose-type N-glycans on the antibodies and Fc fusion proteins of the invention. Also disclosed are methods of using such antibody-based therapeutics for targeted killing of cells in a mammal, including therapeutic methods of treating cancers, autoimmune diseases and other diseases.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: April 20, 2010
    Assignee: Genzyme Corporation
    Inventors: John M. McPherson, Tim Edmunds, Qun Zhou
  • ANTIBODY-BASED THERAPEUTICS WITH ENHANCED ADCC ACTIVITY
    Publication number: 20070092521
    Abstract: Methods for producing antibody-based therapeutics with enhanced ADCC activity are disclosed. The enhanced ADCC activity is attributed to oligomannose-type N-glycans on the antibodies and Fc fusion proteins of the invention. Also disclosed are methods of using such antibody-based therapeutics for targeted killing of cells in a mammal, including therapeutic methods of treating cancers, autoimmune diseases and other diseases.
    Type: Application
    Filed: October 20, 2006
    Publication date: April 26, 2007
    Inventors: John McPherson, Tim Edmunds, Qun Zhou